Citigroup Inc Io Biotech, Inc. Call Options Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IOBT
# of Institutions
23Shares Held
16.5MCall Options Held
0Put Options Held
0-
Novo Holdings Hellerup, G72.51MShares$2.06 Million0.07% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.53MShares$1.25 Million0.09% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.39MShares$1.14 Million0.0% of portfolio
-
Marshall Wace, LLP London, X01.05MShares$863,1570.0% of portfolio
-
Bank Of America Corp Charlotte, NC800KShares$655,9610.0% of portfolio
About IO Biotech, Inc.
- Ticker IOBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,815,300
- Market Cap $23.6M
- Description
- IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in ph...